Core Viewpoint - The company, Xinli Cheng (002219), confirmed on September 30 that there are no undisclosed matters that should have been disclosed to investors [1] Group 1 - The company addressed investor inquiries on an interactive platform, stating that it does not have any undisclosed matters [1] - Previous accounting error corrections have not led to any investigations or penalties from the China Securities Regulatory Commission (CSRC) [1] - The company will not be subject to risk warnings due to the accounting error corrections [1]

Core Viewpoint - The launch of the first foreign-funded consumption REIT, Huaxia CapitaLand Commercial REIT, marks a significant step towards the internationalization and diversification of China's public REITs market, reflecting deepening cooperation between China and Singapore in cross-border investment [1][5]. Group 1: Market Expansion and Internationalization - Huaxia CapitaLand Commercial REIT is the first consumption REIT initiated by an international real estate asset management company in China, symbolizing a milestone in the internationalization of the Chinese REITs market [1][5]. - The listing of Huaxia CapitaLand Commercial REIT demonstrates innovative attempts in cross-border investment between China and Singapore, enhancing the connectivity of capital markets [3][4]. - The successful issuance of this REIT is expected to attract more international capital into China's consumption market, creating a new paradigm for global capital participation [5][6]. Group 2: Asset Management and Operational Strategy - CapitaLand Investment, as the strategic investor and asset management entity, holds a 20% stake in the REIT and aims to leverage its extensive experience in the Singapore REITs market to strengthen the domestic REITs ecosystem [1][3]. - The REIT includes two underlying assets, located in Guangzhou and Changsha, with a total construction area of 168,405 square meters and an overall occupancy rate of approximately 96% as of March 31, 2025 [7][10]. - The REIT's operational strategy focuses on localizing the entire "fundraising, investment, management, and exit" chain, transitioning domestic REITs from mere financing tools to comprehensive asset management platforms [6][11]. Group 3: Market Performance and Future Outlook - The consumption REITs sector has shown robust performance, achieving a comprehensive return rate of 35% in the first half of the year, driven by supportive policies and regulatory facilitation [6][11]. - The issuance of Huaxia CapitaLand Commercial REIT attracted significant investor interest, with subscription funds reaching 3,091.7 billion yuan, 135.2 times the intended fundraising scale [10]. - The ongoing trends of consumption upgrade and capital market reform are expected to position consumption REITs as key instruments for revitalizing existing assets, promoting upgrades, and serving domestic demand [11].

Core Viewpoint - New Mile (002219.SZ) announced the release of its chairman Lin Yanglin from detention, which began in July due to an investigation by the Taiyuan Municipal Xiaodian District Supervisory Committee. The company stated that the matters involved are unrelated to its operations [1][2]. Company Overview - New Mile focuses on medical services and traditional Chinese medicine, operating a "1+N" innovative service model based on tertiary hospitals and a new elderly care model combining elderly hospitals and care centers. As of mid-2023, the company has established six regional medical centers and operates 24 hospitals, including 4 tertiary hospitals and 13 secondary or higher-level hospitals [2]. - The company produces a series of traditional Chinese medicines under the "Duyiwei" brand, with 80 varieties including Duyiwei capsules and tablets, primarily used for post-surgical pain and other conditions [2]. Recent Developments - Lin Yanglin was previously subjected to regulatory discussions by the Gansu Securities Regulatory Bureau due to multiple financial accounting irregularities, which resulted in inaccurate financial disclosures for several reporting periods. Both Lin and the financial director Liu Jun were held primarily responsible for these violations [3]. - In the first half of 2023, New Mile reported a significant decline in performance, with revenue of 1.588 billion yuan, down 20.63% year-on-year, and a net profit of 7.4311 million yuan, down 88.25% year-on-year, attributed to the impact of medical insurance policies and centralized procurement of traditional Chinese medicine [3]. Financial Performance - The company experienced a decrease in inpatient visits and average costs due to ongoing adjustments in medical insurance payment policies, although gross margin improved by 1 percentage point. The gross margin for the pharmaceutical segment was 40.47%, with a 4.7 percentage point decline in gross margin for core products following centralized procurement [4]. - New Mile's hospitals maintained stable outpatient volumes, but inpatient volumes decreased by approximately 9%, and average inpatient costs fell by about 12% [4]. Future Outlook - The company aims to become the "first stock in the silver economy," aligning its health industry strategy with national policies addressing population aging. The implementation of integrated medical and elderly care models is a long-term strategic choice for the company [4].

新里程健康科技集团股份有限公司 证券简称：新里程 证券代码：002219 公告编号：2025-050 新里程健康科技集团股份有限公司 关于为下属医院提供担保的进展公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、担保情况概述 新里程健康科技集团股份有限公司（以下简称"新里程"或"公司"）于 2025 年 4 月 28 日召开第六届董事会第三十三次会议，2025 年 5 月 19 日召开 2024 年 年度股东大会，审议通过了《关于为子公司提供担保额度预计的议案》，同意公 司为相关子公司未来 12 个月向相关合作银行等金融机构申请综合授信额度提供 连带责任担保，额度总计为人民币 181,400 万元（具体内容详见公司于 2025 年 4 月 29 日在巨潮资讯网上披露的《关于为子公司提供担保额度预计的公告》，公 告编号：2025-018）。 公司与招商银行股份有限公司大连分行（以下简称"招商银行大连分行"） 签署了《最高额不可撤销担保书》（合同编号：411XY250728T00009301），公司为 瓦房店第三医院有限责任公司（以下简称"瓦房店第三医院"）向 ...

Core Viewpoint - The company has approved a total of 1.814 billion yuan in joint liability guarantees for its subsidiaries over the next 12 months, indicating a strategic move to support its healthcare operations [1] Group 1: Guarantees and Financial Support - The company has agreed to provide joint liability guarantees amounting to 300 million yuan and 500 million yuan for its wholly-owned subsidiaries, Wafangdian Third Hospital and Lankao First Hospital, respectively [1] - The guarantee period for both contracts is set at three years, reflecting the company's commitment to its subsidiaries [1] - As of June 30, the actual guarantee balance for the subsidiaries stands at 702 million yuan, which constitutes 35.39% of the most recent audited net assets, indicating a significant level of financial backing [1] Group 2: Risk Management - The board of directors believes that the risks associated with these guarantees are controllable and will not harm the interests of the company and its shareholders [1]

Core Viewpoint - The chairman of New Mileage, Lin Yanglin, has had his detention measures lifted and is now able to resume his duties, with the company's operations reported to be normal [1][3]. Group 1: Chairman's Status - Lin Yanglin was previously detained by the Taiyuan Municipal Xiaodian District Supervisory Committee for investigation, but the company confirmed that the matter was unrelated to its operations [1][3]. - Following the lifting of the detention, Lin Yanglin is back to fulfilling his responsibilities as chairman, and the company’s production and operational status is reported as normal [3]. - The company had previously indicated that the investigation would not have a significant adverse impact on its operations [3]. Group 2: Financial Performance - In the first half of the year, New Mileage reported a revenue of 1.588 billion yuan, a year-on-year decrease of 20.63%, and a net profit attributable to shareholders of 7.4311 million yuan, down 88.25% year-on-year [5]. - The medical services segment generated 1.38 billion yuan in revenue, while the pharmaceutical segment brought in 210 million yuan [5]. - The gross margin for the medical segment was 26.34%, which increased by 1 percentage point year-on-year, despite a decrease in inpatient visits and average costs due to ongoing adjustments in medical insurance payment policies [5]. - The pharmaceutical segment's gross margin was 40.47%, down 4.69 percentage points, primarily due to a decrease in sales prices following centralized procurement of core products [5]. Group 3: Market Dynamics - New Mileage participated in a national centralized procurement initiative for traditional Chinese medicine, with its product series "Duyiwei" expected to be selected for procurement [6]. - The implementation of centralized procurement faced delays, leading to a significant drop in sales initially, but sales have recently rebounded as confidence in the market has improved [6].

Core Viewpoint - The chairman of New Mileage, Lin Yanglin, has had his detention lifted, allowing him to resume his duties as chairman of the company [1] Company Summary - On September 22, New Mileage (002219) announced that it received a notification from Lin Yanglin's family regarding the lifting of his detention by the Taiyuan Municipal Xiaodian District Supervisory Committee [1] - The company confirmed that Lin Yanglin is now able to perform his responsibilities as chairman, and the company's production and operational status remains normal [1] - Xu Minggui will no longer act on behalf of Lin Yanglin as chairman [1]

Core Points - The company Xinlicheng (002219) announced on September 22 that its chairman Lin Yanglin has had the detention measures lifted by the Taiyuan City Xiaodian District Supervisory Committee [2] - Following the lifting of the detention, Lin Yanglin is now able to perform his duties as chairman normally, and the company's production and operational status is reported to be normal [2] - The company also stated that Xu Minggui will no longer act as the interim chairman [2]

Core Viewpoint - The company announced that its chairman, Mr. Lin Yanglin, has been released from detention and is able to resume his duties, indicating a return to normal operations for the company [1] Group 1 - The company received a notification from Mr. Lin Yanglin's family regarding the release from detention by the Taiyuan Municipal Xiaodian District Supervisory Committee [1] - The supervisory committee has officially lifted the detention measures against Mr. Lin Yanglin as of September 21, 2025 [1] - Mr. He Minggui will no longer act as the interim chairman, as Mr. Lin Yanglin is now able to fulfill his responsibilities as chairman [1]

Core Viewpoint - The company announced that its chairman, Lin Yanglin, has been released from detention and is able to resume his duties, indicating a return to normal operations for the company [1] Company Updates - Lin Yanglin was previously under investigation by the Taiyuan Municipal Xiaodian District Supervisory Committee, which has now issued a notice of release from detention [1] - Following the release, Lin Yanglin is expected to fulfill his responsibilities as chairman, and Xu Minggui will no longer act in this capacity [1] - The company's production and operational status is reported to be normal [1]